Inclusion Criteria:

- Males or females at least 18 years of age

- Patients with relapsed or refractory Acute myelogenous leukemia (AML) or AML
secondary to myelodysplastic syndromes, myeloproliferative neoplasm, or chronic
myelogenous leukemia

- Eastern Oncology Cooperative Group (ECOG) performance status 0-2 and considered
likely to complete at least 4 weeks of therapy

Exclusion Criteria:

- With the exception of alopecia, any unresolved toxicities from prior therapy greater
than CTCAE grade 1 at the time of starting study treatment.

- As judged by the investigator, any evidence of severe or uncontrolled systemic
diseases, including uncontrolled hypertension, active bleeding diatheses, or active
infection including hepatitis B, hepatitis C and HIV.

- Active heart disease including myocardial infarction within the last 3 months,
symptomatic coronary artery disease, clinically significant arrhythmias not
controlled by medication or uncontrolled congestive heart failure

- Prior allogeneic transplant requiring immunosuppressive therapy (Patients with prior
allogeneic transplants who remain clinically stable for ≥ 2 weeks or more off
immunosuppressive therapy, are eligible) • White blood cell count ≥ 100,000/mm3
(100x10*9/L)